chartexchange

Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire Inc. | Nov 16, 2026 8:00 AM EST

CAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

Read original article